ProCE Banner Activity

Key Ongoing Clinical Trials in HR-Positive/HER2-Negative Early-Stage Breast Cancer

Slideset Download
This slideset accompanies an expert analysis of ongoing clinical trials that are most likely to inform care of patients with HR-positive/HER2-negative early-stage breast cancer.

Released: September 22, 2022

Expiration: September 21, 2023

No longer available for credit.

Share

Faculty

Denise A. Yardley

Denise A. Yardley, MD

Senior Investigator
Breast Cancer Research Program
The Sarah Cannon Research Institute and Tennessee Oncology
Nashville, Tennessee

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Lilly

Merck Sharp & Dohme Corp.

Partners

Smart Patients

ProCE Banner

Faculty Disclosure

Primary Author

Denise A. Yardley, MD

Senior Investigator
Breast Cancer Research Program
The Sarah Cannon Research Institute and Tennessee Oncology
Nashville, Tennessee

Denise A. Yardley, MD: researcher (paid to institution): AbbVie, Amgen, Biomarin, Biothera, Clovis, Incyte, Innocrin, Lilly, MacroGenics, MedImmune, Medivation, Merck, Merrimack, Nektar, Novartis, NSABP, Pfizer, Polyphor, Roche/Genentech, Tesaro; consultant (paid to institution): Athenex, bioTheranostics, G1 Therapeutics, Immunomedics, Lilly, Merck, Novartis, Pfizer, Sanofi-Aventis.